What smart money is saying about Soleno Therapeutics
SLNO
No fund has written a full thesis on Soleno Therapeutics in our archive, but 2 fund letters report a position in it — most recently Timessquare US Small Cap Growth Strategy in September 2025.
Get an email when a fund writes about it
2
Reported positions
1
Bought
1
Sold
2
Letters
Position history
Between Q1 2025 and Q3 2025, 2 fund letters reported a position in Soleno Therapeutics — 1 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2025 | 1 | 1 | 0 | 0 |
| Q1 2025 | 1 | 0 | 1 | 0 |
Fund activity · 2 positions · 2 moves
- September 2025
“We felt differently about biopharma developer Soleno Therapeutics and added to our holdings as its shares pulled back by -19%.”
Soleno Therapeutics - March 2025
“Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases. The FDA granted approval of Vyvkat for treating Prader Willi syndrome, a rare genetic disorder that causes life-threatening obesity in children. That development served to boost the stock price by 60% and we decided to book some of the profits by cutting back on the investment.”
Soleno Therapeutics
Read the letters behind these Soleno Therapeutics positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger